When your stock jumps 400% in a year, you might think it's time to sit back and enjoy the ride. 3SBio Inc. (1530.HK) has other ideas. The Chinese drug developer just raised $400 million through a share placement and announced it's ditching its profitable hair-loss business entirely. The message is clear: we're going all-in on next-generation cancer drugs, and we need cash to make it happen.

Here's the setup. Back in May, 3SBio struck a blockbuster deal with Pfizer (PFE) that sent its stock into orbit. Pfizer paid up to $1.25 billion upfront for international rights to a bispecific antibody drug targeting PD-1/VEGF pathways. That's the largest deal of its kind ever signed by a Chinese company. The stock has been on a tear ever since, pushing the company's market value above HK$70 billion.

Why Raise Money When You're Already Flush?

On the surface, 3SBio doesn't look cash-starved. The Pfizer payment is expected to hit the books in the third quarter. First-half net profit came in at 1.36 billion yuan. So why go back to the market now?

On December 2, the company announced it was placing 105 million shares at HK$29.62 each, representing about 4.14% of its enlarged share capital. That's a 6.5% discount to the previous closing price, and after fees, the net proceeds should come to about HK$3.09 billion. The shares dipped 4.61% on the news and fell another 3.04% the next day, but they're still up more than 400% year-to-date.

The answer lies in where that money's going. About 80% of the proceeds will fund research and development, including ongoing clinical trials in China and the United States, expanding approved drugs to treat additional conditions, and building out global infrastructure. The remaining 20% goes to working capital. Translation: developing cutting-edge drugs is expensive, and 3SBio wants a war chest ready before the bills come due.

This isn't a sudden pivot. The company has been ramping up R&D spending steadily, from 690 million yuan in 2022 to 1.33 billion yuan in 2024. In the first half of 2025, research costs were 15% higher than the same period a year earlier. Right now, 3SBio has 30 experimental drugs in its pipeline, including 27 innovative treatments targeting oncology and autoimmune diseases. Four of those candidates are running parallel clinical trials in China and the U.S., preparing for regulatory filings in both markets. Cross-border drug development doesn't come cheap.

The Hair-Loss Business Gets the Chop

Around the same time as the capital raise, 3SBio announced it's spinning off Mandi International, its subsidiary that dominates China's hair-loss treatment market. Mandi holds a 71% share of the market for minoxidil, an alopecia medication, and has been the category leader for a decade.

By any measure, Mandi is a cash cow. First-half revenues hit 743 million yuan, with an impressive gross margin of 81.1% and net profit of 174 million yuan. Most companies would hold onto a business like that to help subsidize their research ambitions. Not 3SBio.

The company is divesting its entire 87.16% stake through what's known as distribution in kind. Shareholders will receive a pro-rata stake in Mandi as an independent listed entity, and 3SBio will walk away with zero equity interest. It's a clean break, unlike the approach taken by companies like WuXi Biologics (2269.HK), which kept a controlling stake when it spun off WuXi XDC (2268.HK), its antibody-drug conjugate unit.

Why cut ties with a profitable business? Simple: consumer healthcare doesn't fit the strategic vision anymore. 3SBio wants to be a pure-play pharmaceutical innovator focused on novel drugs for cancer and autoimmune conditions. Hair-loss treatments, however lucrative, are off-brand. The move signals the company's confidence that it has enough cash reserves and a strong enough late-stage pipeline to survive without Mandi's steady earnings stream.

Preparing for the Long Haul

Drug development is one of the most capital-intensive businesses on earth. Most companies hang onto their cash-generating operations for exactly that reason. By divesting Mandi, 3SBio is betting that the Pfizer windfall, combined with this fresh capital raise, will be enough to carry it through the expensive years ahead.

The company's current valuation suggests the market sees room for growth. 3SBio trades at a price-to-earnings ratio of roughly 28 times, well below the approximately 60 times commanded by Hengrui Pharma (600276.SH), another established Chinese innovator. That gap could indicate upside potential if 3SBio successfully advances its drug candidates through trials and brings them to market.

With capital secured and the spin-off underway, the real test begins. Can 3SBio deliver on its ambitions and produce meaningful breakthroughs in its cancer and autoimmune drug pipeline? The company has placed its bets, raised the stakes, and gone all-in on innovation. Now investors will be watching to see if the hand pays off.